Longer colonoscopy withdrawal times associated with lower cancer rate
the ONA take:
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates, according to research by a Veterans Affairs team.
The link between colonoscopy withdrawal time and patient outcomes is already known; this study provides strong evidence to support clinical guidelines regarding colonoscopy withdrawal times. Current guidelines recommend a withdrawal time of 6 minutes or more.
In this study, data on colonoscopies performed over 6 years by 51 gastroenterologists in a large community practice were evaluated. The average withdrawal time for the practice was 8.6 minutes; however, approximately 10% of the doctors had individual averages of less than 6 minutes.
The researchers then reviewed the state’s cancer registry for colorectal cancer cases among patients who had been screened at the practice during the study period, including cancers that occurred within 5 years of the last screening.
Referred to as interval cancers, these cancers are assumed to have developed from polyps that were either not detected during the colonoscopy, or not fully removed.
The American College of Gastroenterology acknowledges that some colons can be effectively examined in less than 6 minutes, but these findings show longer colonoscopy withdrawal times correlate with lower risk for interval cancer. The researchers report that further research is needed on quality measures for this screening procedure.
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|